Adjuvant trastuzumab for breast cancer: An increasingly common ethical and economic conundrum

BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7526.1202-b (Published 17 November 2005) Cite this as: BMJ 2005;331:1202
  1. Matthew L Grove (Matthew.Grove@northumbria-healthcare.nhs.uk), consultant rheumatologist
  1. Tyneside General Hospital, North Shields NE29 8NH

    EDITOR—The advent of increasingly expensive and effective treatments over the next few years is likely to make this kind of ethical discussion even more common.1

    However, the £20 000 headline figure for a course of trastuzumab obscures the real cost of using this agent. In the original paper 261 adverse outcomes occurred in 1679 patients …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription